St. Jude Medical Launches the Industry's First Quadripolar Pacing System in India
September 07 2011 - 8:01AM
Business Wire
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced the approval of the industry’s first
quadripolar pacing system for cardiac resynchronization therapy
defibrillators (CRT-Ds) in India. The Promote Quadra™ CRT-D offers
physicians the ability to more effectively and efficiently manage
the ever-changing pacing needs of patients with heart failure.
Cardiac resynchronization therapy, which can be delivered in an
implantable cardioverter defibrillator (ICD) or a pacemaker,
resynchronizes the beating of the heart's lower chambers
(ventricles), which often beat out of sync in heart failure
patients. Studies have shown that CRT can improve the quality of
life for many patients with heart failure, a progressive condition
in which the heart weakens and loses its ability to pump an
adequate supply of blood. Approximately 23 million people worldwide
are afflicted with congestive heart failure (CHF), and 2 million
new cases of CHF are diagnosed each year worldwide.
The quadripolar technology integrates multiple pacing
configurations and features that enable physicians to optimize the
system at implant and throughout the life of the patient, as well
as better manage common complications without having to expose the
patient to additional surgeries. St. Jude Medical is the only
company to offer quadripolar pacing.
The Quartet™ left ventricular pacing lead is used as part of the
quadripolar pacing system. It is the first lead to feature four
electrodes that enable up to 10 pacing configurations. Multiple
pacing configurations allow the physician more options including
pacing closer to the base of the left ventricle, which recent
studies associate with better patient outcomes and which may be
less possible with leads that have only two electrodes. The
quadripolar pacing electrodes also provide physicians additional
benefits, such as pacing around scar tissue in the heart and
avoiding the most common pacing complications.
Common pacing complications that can occur in patients implanted
with a CRT system include high pacing thresholds and unintentional
phrenic nerve or diaphragmatic stimulation. Patients with high
pacing thresholds require significantly higher energy to pace the
heart; this may reduce the device’s battery life or cause pacing to
fail. Phrenic nerve and diaphragmatic stimulation occur when the
electrical output from a device inadvertently activates the
diaphragm muscle (either directly or via the phrenic nerve),
causing hiccups upon each pacing stimulus. Both high pacing
thresholds and phrenic nerve or diaphragmatic stimulation are often
due to the location of the pacing lead electrode.
“High pacing thresholds and phrenic nerve capture have been
major problems with LV leads. This new quadripolar LV lead offers
different pacing vectors and helps us to choose a vector which is
devoid of Phrenic nerve capture. Altering pacing polarity may offer
a lower pacing threshold, which is likely to improve the battery
longevity," said Dr. Calumbur Narsimhan, Director of
Arrhythmia-Electrophysiology Services at CARE Hospital in
Hyderabad.
The Promote Quadra CRT-D and Quartet pacing lead have both
received European CE Mark approval.
About St. Jude Medical
St. Jude Medical develops medical technology and services that
focus on putting more control into the hands of those who treat
cardiac, neurological and chronic pain patients worldwide. The
company is dedicated to advancing the practice of medicine by
reducing risk wherever possible and contributing to successful
outcomes for every patient. St. Jude Medical is headquartered in
St. Paul, Minn. and has four major focus areas that include:
cardiac rhythm management, atrial fibrillation, cardiovascular and
neuromodulation. For more information, please visit sjm.com.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 1, 2011 and Quarterly Report on Form 10-Q for the fiscal
quarter ended July 2, 2011. The Company does not intend to update
these statements and undertakes no duty to any person to provide
any such update under any circumstance.
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024